Project and pipeline - clinical project - Nanjing Leads Biolabs Co.,Ltd

PIPELINE & PRODUCT DEVELOPMENT

Clinical Programs

Our R&D pipeline includes monoclonal antibodies and bispecific antibodies. While developing monotherapy, Nanjing Leads Biolabs is also committed to developing combination therapies that can provide valuable and long-term benefits to cancer patients.

We have more than 9 kinds of independently developed antibodies，of which LBL-007 has obtained FDA clinical trial approval and clinical trial implied license in China, and 2 clinical studies have been launched. LBL-003 and LBL-015 also have obtained FDA clinical trial approval and clinical trial implied license in China , and the clinical trial is about to start; Other R&D products will also start the clinical study.

LBL-007

LBL-007 is an anti-LAG-3 fully human monoclonal antibody injection developed by NanJing Leads Biolabs.In China, clinical studies of LBL-007 monotherapy are currently underway, and 5 dose groups of climbing have been completed. Meanwhile, LBL-007 in combination with Toripalimab for melanoma has completed 3 dose groups of climbing and will soon start preparing for dose expansion.LBL-007 is an anti-LAG-3 fully human monoclonal antibody injection independently developed by NanJing Leads Biolabs. In China, the clinical study of LBL-007 as monotherapy is currently underway, and 5 dose groups of the dose escalation study have been completed. At the same time, a clinical study of LBL-007 in combination with Toripalimab Injection for first-line treatment of melanoma has been officially initiated. We will also investigate the efficacy of LBL-007 as a combination therapy for the treatment in different solid tumors.

LBL-003

LBL-003 is a recombinant fully human anti-TIM-3 monoclonal antibody for injection，which has obtained FDA clinical trial approval and clinical trial implied license in China, and will soon start the phase I clinical trial.

LBL-015

LBL-015 is an anti-PD-1antibody-transforming factor β (TGF-βR2)

bifunctional antibody fusion protein independently developed by NanJing Leads Biolabs. lt has obtained FDA clinical trial approval and clinical trial implied license in China, and will soon start Phase l/ll clinical trial.